Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA approves Gilead’s hep C drug Epclusa

The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s drug for treating chronic hepatitis C virus infection.

Read More »

Senate Democrats seek new deal on Zika funding fight

U.S. Senate Democrats called for bipartisan talks in the funding fight over Zika, saying a Republican proposal was “extreme and insufficient” to combat the virus and was full of “ideological poison pill riders.”

Read More »

Can smartphones help improve heart attack treatment?

Smartphones, social media and crowdsourcing all have the potential to help people get faster, better treatment for heart attacks and strokes, according to the American Heart Association (AHA).

Read More »

In Light of Two Major Failed Trials, FORUM Pharma Closes Its Doors This Week

It’s official – Waltham, Massachusetts-based FORUM Pharmaceuticals will be shuttering its doors before the Fourth of July holiday.

Read More »

Infinity Pharma Cuts Jobs by 58% as AbbVie Terminates Duvelisib Collaboration Deal

Infinity Pharmaceuticals announced that North Chicago-based AbbVie chose to terminate its collaboration deal to develop and commercialize duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which are associated with malignant B-cells.

Read More »

Mayne Pharma Acquiring 42 Generic Drugs

Australian company Mayne Pharma is acquiring 37 approved drugs and five products that have been filed with the U.S. FDA from Teva Pharmaceutical Industries and Allergan.

Read More »

Pfizer invests in its first biotech hub in Asia

Pfizer Inc. will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world’s no. 2 drugs market.

Read More »

Supreme Court refuses to review prenatal test patent dispute

The U.S. Supreme Court rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for patents.

Read More »

NewLink Genetics Stock Slides, Company Lays Off 87 After Failed Trial

After announcing that its Phase III clinical trial for algenpantucel-KL for resected pancreatic cancer failed in May, Ames, Iowa-based NewLink Genetics confirmed that it has laid off 87 employees.

Read More »

AnGes Terminates Phase III HGF Plasmid, Starts New Plan

AnGes MG Inc. announced its decision to amend the global development strategy of HGF Plasmid (AMG0001, Beperminogene Perplasmid) for the treatment of critical limb ischemia.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!


Ad Right Bottom